氨甲酰化与贫血对糖尿病合并慢性肾脏病患者糖化血红蛋白与肾脏结局关联的影响
研究纳入1,516例糖尿病合并慢性肾脏病(CKD)患者,评估糖化血红蛋白(HbA1c)与CKD进展的关联是否受氨甲酰化白蛋白(C-Alb)和贫血影响。中位随访6.9年,763例发生CKD进展;总体HbA1c较高与CKD进展风险增加相关(校正HR 1.07,95%CI 1.02-1.13),但该关联在最高C-Alb四分位组不再存在,且受贫血影响(交互P=0.022和0.025)。
要点
- 总体HbA1c较高与CKD进展风险增加相关(校正HR 1.07,95%CI 1.02-1.13)。
- 最高C-Alb四分位组中HbA1c与CKD进展的关联不再存在(交互P=0.022)。
- 贫血也修饰HbA1c与CKD进展的关联(交互P=0.025)。
核心结论
- 在糖尿病合并CKD患者中,HbA1c与CKD进展的关联受氨甲酰化和贫血修饰。
研究设计与样本
- 来自慢性肾功能不全队列(CRIC)研究的1,516例糖尿病合并CKD参与者。
- 采用Cox回归模型评估HbA1c与CKD进展的关联,并按C-Alb四分位和贫血分层。
主要发现
- 平均eGFR为38.1 mL/min/1.73 m2,平均HbA1c为7.5%(58 mmol/mol),C-Alb中位数为8.4 mmol/mol。
- HbA1c在较高C-Alb四分位组中较低。
- 中位随访6.9年期间,763例参与者发生CKD进展。
- 总体HbA1c较高与CKD进展风险增加相关(校正HR 1.07,95%CI 1.02-1.13)。
- 最高C-Alb四分位组中HbA1c与CKD进展不再相关,而各较低C-Alb四分位组中CKD进展风险呈单调增加(交互P=0.022);贫血也修饰该关联(交互P=0.025)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Glycated hemoglobin (HbA1c) can predict risk for microvascular complications in patients with diabetes. However, HbA1c's reliability in chronic kidney disease (CKD) has been questioned, with concerns including competition from another posttranslational protein modification, carbamylation, acting on the same amino groups as glycation, and anemia with reduced erythrocyte lifespans leading to altered glycation accumulation. We investigated whether carbamylation and anemia modify the impact of HbA1c on renal outcomes in patients with diabetes and CKD. RESEARCH DESIGN AND METHODS: In 1,516 participants from the Chronic Renal Insufficiency Cohort study with diabetes and CKD, Cox regression models were applied to evaluate the association between HbA1c and CKD progression (composite of end-stage kidney disease or 50% decline in estimated glomerular filtration rate [eGFR]), stratified by carbamylated albumin (C-Alb) quartiles and anemia. RESULTS: The mean eGFR was 38.1 mL/min/1.73 m2, mean HbA1c was 7.5% (58 mmol/mol), and median C-Alb was 8.4 mmol/mol. HbA1c was lower in the higher C-Alb quartiles. During a median follow-up of 6.9 years, 763 participants experienced CKD progression. Overall, higher HbA1c was associated with an increased risk of CKD progression (adjusted hazard ratio 1.07 [95% CI 1.02-1.13]). However, using stratified analyses, HbA1c was no longer associated with CKD progression in the highest C-Alb quartile, but did show a monotonic increase in CKD progression risk across each lower C-Alb quartile (P-interaction = 0.022). Anemia also modified the association between HbA1c and CKD progression (P-interaction = 0.025). CONCLUSIONS: In patients with coexisting diabetes and CKD, the association between HbA1c and CKD progression is modified by carbamylation and anemia.
引用
- Tang M, Berg A, Rhee EP, et al. The Impact of Carbamylation and Anemia on HbA1c's Association With Renal Outcomes in Patients With Diabetes and Chronic Kidney Disease. Diabetes Care. 2023. PMID: 36399777. doi:10.2337/dc22-1399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。